Jean Tang, MD, PhD is co-founder of PellePharm and serves on the PellePharm board of directors. She is a practicing dermatologist and associate professor of dermatology at Stanford University. Gorlin Syndrome is a rare, genetic, disease characterized by mutations in the tumor suppressor gene encoding Patched1 (PTCH1), which acts as the primary inhibitor of the hedgehog signaling pathway. This leads to hundreds of basal cell carcinomas, especially on the face and sun-exposed areas.

Basal Cell Carcinoma Nevus Syndrome (BCCNS) Life Support Network is dedicated to providing counseling and support services to children and adults manifesting the genetic disorder known as Basal Cell Carcinoma Nevus Syndrome (BCCNS, NBCCS, or Gorlin-Goltz syndrome).

Basal Cell Carcinoma Nevus (aka Gorlin or Gorlin – Goltz) Syndrome is a rare disorder that can affect many organ systems in the human body. This syndrome is caused by a genetic mutation that can be inherited or appear on its own. The incidence is low, in that approximately 1 in 27,000 people have BCCNS.